Chronic Obstructive Pulmonary Disease (COPD) is a form of respiratory disease causing difficulty in a person to exhale. Various medications for treatment of COPD include; bronchodilators, phosphodiesterase-4 (PDE4) inhibitors, corticosteroids, and other medication varieties. On the other hand, two drug methods, also known as ‘combination therapy’ is one of the recent techniques in combination therapies.

A combination therapy is a method or technique that involves combination of more than one drug variety for the treatment of COPD. Various types of combination therapies include, fixed combinations of agents, two drug combination and triple combinations. Triple combinations are recent discoveries in the category of combination therapy for COPD prognosis. In most cases combination therapies are inhaled rather than orally administered. One of the most recent examples of triple combination therapy is the combination of an inhaled corticosteroid called fluticasone furoate, a long-acting muscarinic antagonist called umeclidinium, and a long-acting beta2-adrenergic agonist called vilanterol. However, dual combinations mainly use combination of long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs).

Combination therapies are cost effective and more efficient in treating COPD. The most common and economic drug for combination medication are ipratropium and albuterol, and fluticasone and salmeterol.